Regeneron Pharmaceuticals
REGN
816 hedge funds and large institutions have $36.9B invested in Regeneron Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 200 funds opening new positions, 281 increasing their positions, 254 reducing their positions, and 79 closing their positions.
153% more first-time investments, than exits
New positions opened: 200 | Existing positions closed: 79
38% more funds holding in top 10
Funds holding in top 10: 16 → 22 (+6)
33% more capital invested
Capital invested by funds: $27.7B → $36.9B (+$9.19B)
16% more funds holding
Funds holding: 702 → 816 (+114)
11% more repeat investments, than reductions
Existing positions increased: 281 | Existing positions reduced: 254
1.63% more ownership
Funds ownership: 68.47% → 70.11% (+1.6%)
9% more call options, than puts
Call options by funds: $1.04B | Put options by funds: $959M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.16B |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$197M |
| 3 |
BlackRock
New York
|
+$189M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$177M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$89.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harris Associates
Chicago,
Illinois
|
-$846M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$495M |
| 3 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
-$244M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$154M |
| 5 |
HM
HealthCor Management
New York
|
-$140M |
REGN Hedge Fund Activity: Q1 2020 in Review
816 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2020, worth a combined $36.9B — up 33% from $27.7B a quarter earlier.
Buyers outnumbered sellers: 200 funds opened new REGN positions and 79 closed out — a net gain of 121 holders — while 281 added to existing stakes and 254 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.16B. The largest seller was Harris Associates, cutting an estimated $846M.
- 816 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2020, up from 702 in Q4 2019.
- Funds reported $36.9B of Regeneron Pharmaceuticals stock for Q1 2020, up 33% quarter-over-quarter.
- 200 funds opened new Regeneron Pharmaceuticals positions in Q1 2020 and 79 closed out, a net change of +121 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2020 was Fidelity Investments, an estimated $2.16B added.
- The largest Regeneron Pharmaceuticals seller in Q1 2020 was Harris Associates, an estimated $846M sold.
Based on aggregated 13F filings for Q1 2020.